The Overall Hemostasis Potential: A Laboratory Tool for the Investigation of Global Hemostasis

ABSTRACT

A simple and rapid global haemostatic assay for determination of the overall hemostasis potential (OHP) in plasma represents a new approach in detecting alterations in the delicate balance between coagulation and fibrinolysis. The assay is based on repeated spectrophotometric registration of the fibrin-aggregation curve in platelet-poor plasma containing small amounts of exogenous thrombin, tissue-type plasminogen activator, and calcium. The overall coagulation potential and overall fibrinolytic potential are supplementary parameters of OHP, providing details of underlying changes in coagulation and/or fibrinolysis. The OHP assay was evaluated in connection with hypercoagulation in normal pregnancy, preeclampsia, some thrombophilias, coronary heart disease, diabetes, stroke, and vascular surgery as well as with hypocoagulability, especially in patients with hemophilia A or B. Preliminary results also indicate the possible usefulness of the assay in monitoring anticoagulant treatments. Large prospective clinical trials are needed before the method can be recommended for routine clinical application.

KEYWORDS

Global haemostatic assay - Overall Haemostatic Potential (OHP) - hypercoagulability

REFERENCES

• 1 Brummel K E, Paradis S G, Butenas S, Mann K G. Thrombin functions during tissue factor-induced blood coagulation.  Blood. 2002;  100(1) 148-152
• 2 Mann K G, Brummel K, Butenas S. What is all that thrombin for?.  J Thromb Haemost. 2003;  1(7) 1504-1514
• 3 Erban S B, Kinman J L, Schwartz J S. Routine use of the prothrombin and partial thromboplastin times.  JAMA. 1989;  262(17) 2428-2432
• 4 Kitchen S, Cartwright I, Woods T A, Jennings I, Preston F E. Lipid composition of seven APTT reagents in relation to heparin sensitivity.  Br J Haematol. 1999;  106(3) 801-808
• 5 Ray M J. An artefact related to the ratio of sample volume to the blood collection vial size which effects the APTTs of specimens taken to monitor heparin therapy.  Thromb Haemost. 1991;  66(3) 387-388
• 6 Hillarp A, Egberg N, Nordin G, Stigendal L, Fagerberg I, Lindahl T L. Local INR calibration of the Owren type prothrombin assay greatly improves the intra- and interlaboratory variation. A three-year follow-up from the Swedish national external quality assessment scheme.  Thromb Haemost. 2004;  91(2) 300-307
• 7 Hemker H C, Giesen P, AlDieri R et al.. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability.  Pathophysiol Haemost Thromb. 2002;  32(5-6) 249-253
• 8 Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J. Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation.  J Thromb Haemost. 2003;  1(3) 551-558
• 9 Shima M, Matsumoto T, Fukuda K et al.. The utility of activated partial thromboplastin time (aPTT) clot waveform analysis in the investigation of hemophilia A patients with very low levels of factor VIII activity (FVIII:C).  Thromb Haemost. 2002;  87(3) 436-441
• 10 Smith A A, Jacobson L J, Miller B I, Hathaway W E, Manco-Johnson M J. A new euglobulin clot lysis assay for global fibrinolysis.  Thromb Res. 2003;  112(5–6) 329-337
• 11 He S, Bremme K, Blombäck M. A laboratory method for determination of overall haemostatic potential in plasma. I. Method design and preliminary results.  Thromb Res. 1999;  96(2) 145-156
• 12 He S, Antovic A, Blombäck M. A simple and rapid laboratory method for determination of haemostasis potential in plasma. II. Modifications for use in routine laboratories and research work.  Thromb Res. 2001;  103(5) 355-361
• 13 Antovic A, Blombäck M, Sten-Linder M, Petrini P, Holmström M, He S. Possibility of detecting different hypocoagulable states with a modifiable global assay of overall haemostasis potential in plasma.  Blood Coagul Fibrinolysis. 2005;  16(8) 585-596
• 14 Antovic A. Determination of Overall Hemostasis Potential and Fibrin Gel Permeability: Method Development and Application in Research and in Clinical Materials [PhD thesis]. Stockholm, Sweden; Karolinska Institute 2004
• 15 Antovic J P, Yngen M, Ostenson C G et al.. Thrombin activatable fibrinolysis inhibitor and hemostatic changes in patients with type I diabetes mellitus with and without microvascular complications.  Blood Coagul Fibrinolysis. 2003;  14(6) 551-556
• 16 Antovic J P, Rafik Hamad R, Antovic A, Blombäck M, Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?.  Thromb Haemost. 2002;  88(4) 644-647
• 17 Anzej S, Bozic M, Antovic A et al.. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia.  Thromb Res. 2007;  120(1) 39-46
• 18 Rooth E, Wallen H, Antovic A et al.. Thrombin activatable fibrinolysis inhibitor and its relationship to fibrinolysis and inflammation during the acute and convalescent phase of ischemic stroke.  Blood Coagul Fibrinolysis. 2007;  18(4) 365-370
• 19 Antovic A, Blombäck M, Bremme K, Van Rooijen M, He S. Increased hemostasis potential persists in women with previous thromboembolism with or without APC resistance.  J Thromb Haemost. 2003;  1(12) 2531-2535
• 20 Andresen M S, Iversen N, Abildgaard U. Overall haemostasis potential assays performed in thrombophilic plasma: the effect of preactivating protein C and antithrombin.  Thromb Res. 2002;  108(5-6) 323-328
• 21 Andresen M S, Abildgaard U, Liestøl S et al.. The ability of three global plasma assays to recognize thrombophilia.  Thromb Res. 2004;  113(6) 411-417
• 22 Andresen M S, Abildgaard U. Coagulation Inhibitor Potential: a study of assay variables.  Thromb Res. 2005;  115(6) 519-526
• 23 Andresen M S, Eilertsen A L, Abildgaard U, Sandset P M. Hormone therapy and raloxifene reduce the coagulation inhibitor potential.  Blood Coagul Fibrinolysis. 2007;  18(5) 455-460
• 24 Antovic J P, Antovic A, Sten-Linder M, Wramsby M, Blombäck M. Overall hemostatic potential (OHP) assay—a possible tool for determination of prothrombotic pattern in FXII deficiency.  J Thromb Haemost. 2004;  2(11) 2058-2060
• 25 Curnow J L, Morel-Kopp M C, Roddie C, Aboud M, Ward C M. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay.  J Thromb Haemost. 2007;  5(3) 528-534
• 26 Antovic A, Blombäck M, Bremme K, He S. The assay of overall haemostasis potential used to monitor the low molecular mass (weight) heparin, dalteparin, treatment in pregnant women with previous thromboembolism.  Blood Coagul Fibrinolysis. 2002;  13(3) 181-186
• 27 Vedin J, Antovic A, Ericsson A, Vaage J. Hemostasis in off-pump compared to on-pump coronary artery bypass grafting: a prospective, randomized study.  Ann Thorac Surg. 2005;  80(2) 586-593
• 28 Vižintin Cuderman T, Božič M, Antovic A, Peternel P, Stegnar M. Overall haemostasis potential in patients with venous thrombosis before, during and after anticoagulant treatment. Poster presented at: XXI Congress of the International Society on Thrombosis and Haemostasis 2007 Geneva, Switzerland;
• 29 Morel-Kopp M C, Curnow J, Aboud M, Coyle L, Ward C M. Discrepancies between the overall coagulation potential (OCP) assay and international normalised ratio (INR) in warfarin treated patients. Poster presented at: XX Congress of the International Society on Thrombosis and Haemostasis 2005 Sidney, Australia;
• 30 Antovic J P, Antovic A, He S, Tengborn L, Blombäck M. Overall haemostatic potential can be used for estimation of thrombin activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to FVIII.  Haemophilia. 2002;  8(6) 781-586
• 31 Antovic J P, Antovic A. Does recombinant factor VIIa, apart from overall hemostasis, regulate TAFI dependent fibrinolysis? In vitro analysis using overall hemostasis potential (OHP) assay.  Thromb Haemost. 2003;  90(4) 620-627
• 32 Kramkowski K, Mogielnicki A, Chabielska E, Cylwik D, Buczko W. The effect of ‘tissue’ and ‘plasma’ angiotensin converting enzyme inhibitors on overall haemostatic potentials in rats.  Thromb Res. 2006;  117(5) 557-561
• 33 Mogielnicki A, Chabielska E, Pawlak R, Szemraj J, Buczko W. Angiotensin II enhances thrombosis development in renovascular hypertensive rats.  Thromb Haemost. 2005;  93(6) 1069-1076
• 34 Chabielska E, Mogielnicki A, Kramkowski K, Buczko W. Antithrombotic effect of captopril and enalapril in old rats.  Pharmacol Rep. 2005;  57(1) 135-137
• 35 Goldenberg N A, Hathaway W E, Jacobson L, Manco-Johnson M J. A new global assay of coagulation and fibrinolysis.  Thromb Res. 2005;  116(4) 345-356
• 36 He S, Zhu K, Skeppholm M et al.. A global assay of haemostasis which uses recombinant tissue factor and tissue-type plasminogen activator to measure the rate of fibrin formation and fibrin degradation in plasma.  Thromb Haemost. 2007;  98(4) 871-882